Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES

(GILD)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Gilead Sciences : , Insitro to Collaborate on Nonalcoholic Steatohepatitis

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/16/2019 | 07:42am EDT

By Michael Dabaie

Gilead Sciences Inc. (GILD) said it will collaborate with insitro to develop nonalcoholic steatohepatitis therapies.

Under the three-year agreement, insitro's platform will be used to create disease models for NASH and discover targets that have an influence on clinical progression and regression of the disease, Gilead said Tuesday.

Gilead can advance up to five targets identified through this collaboration and will be responsible for chemistry and development.

Insitro will receive an upfront payment of $15 million, with additional near-term payments up to $35 million based on operational milestones. Insitro will be eligible to receive up to $200 million for the achievement of milestones for each of the five Gilead targets and up to low double-digit tiered royalties on net sales.

Write to Michael Dabaie at michael.dabaie@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
08/19Who is next in big pharma's merger spree?
RE
08/16GILEAD SCIENCES : European Medicines Agency Validates Marketing Application for ..
AQ
08/15European Medicines Agency Reviews Arthritis Treatment by Gilead, Galapagos
DJ
08/15STEALTH BIOTHERAPEUTICS : Reports First Half 2019 Financial Results and Recent B..
AQ
08/15GILEAD SCIENCES : Québec Provides Access to Biktarvy® for the Treatment of HIV
AQ
08/13GILEAD SCIENCES : Report
CO
08/12GILEAD SCIENCES : China National Medical Products Administration Approves Biktar..
AQ
08/12GILEAD SCIENCES : China National Medical Products Administration Approves Biktar..
AQ
08/09MARKET SNAPSHOT: Dow Ends Friday Trade Lower But Indexes Chipped Away At Ugly..
DJ
08/09GILEAD SCIENCES : China National Medical Products Administration Approves Biktar..
BU
More news
Financials (USD)
Sales 2019 22 314 M
EBIT 2019 11 591 M
Net income 2019 4 273 M
Debt 2019 3 023 M
Yield 2019 3,97%
P/E ratio 2019 18,1x
P/E ratio 2020 11,1x
EV / Sales2019 3,74x
EV / Sales2020 3,60x
Capitalization 80 344 M
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 80,95  $
Last Close Price 63,44  $
Spread / Highest target 49,7%
Spread / Average Target 27,6%
Spread / Lowest Target -5,42%
EPS Revisions
Managers
NameTitle
Gregg H. Alton Chief Executive & Patient Officer
John C. Martin Chairman
Robin L. Washington CFO, Principal Accounting Officer & Executive VP
John G. McHutchison Chief Scientific Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES1.42%80 344
VERTEX PHARMACEUTICALS10.87%47 223
REGENERON PHARMACEUTICALS-20.74%32 392
GENMAB28.01%13 210
NEUROCRINE BIOSCIENCES, INC.35.88%8 886
BEIGENE LTD--.--%8 765